FertilAI Secures $4.5M to Revolutionize Fertility Treatment with AI-Driven Insights
FertilAI is revolutionizing fertility treatments by leveraging AI to improve predictability, clinical outcomes, and patient experiences
Company Name: FertilAI
Location: Tel Aviv, Israel
Industry: HealthTech, AI-Powered Fertility Solutions
Funding Details:
The company raised $4.5M in funding, led by Longevity Venture Partners and Redseed, with additional contributions from angel investors.
Purpose of Investment:
FertilAI will use the funds to expand its market presence, grow its team, and advance research and development efforts.
Leadership:
FertilAI is led by Rohi Hourvitz, CEO, who drives the company’s mission to improve fertility treatment outcomes through AI innovation.
Product:
FertilAI offers the Fertilane platform, which integrates with clinic electronic medical records (EMRs) to deliver AI-driven insights for fertility treatments. Key features include:
- Optimized Embryo Transfer Timing: Predicts ideal transfer timing to enhance success rates.
- Cycle Management: Supports stimulation cycle decision-making and ovulation tracking.
- Comprehensive Fertility Support: Facilitates timed intercourse and intrauterine insemination (IUI).
- Patient Communication: Includes a mobile app to streamline two-way communication between clinics and patients, enhancing the patient experience.
About the Company:
FertilAI is revolutionizing fertility treatments by leveraging AI to improve predictability, clinical outcomes, and patient experiences. In 2024 alone, its solutions have been adopted by over 50 physicians globally, benefiting more than 20,000 patients. The company is committed to advancing fertility care through cutting-edge technology and personalized insights.
